Life forward Life forward In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Partnering pet therapeutics Partnering pet therapeutics Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Lameness horses collaboration Sleip app artificial intelligence Lameness horses collaboration Sleip app artificial intelligence The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
Making sustainable medicines through eco-design Making sustainable medicines through eco-design Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Our people Our people Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
Be At The Heart Of Every Breakthrough Be At The Heart Of Every Breakthrough Now is the time to cultivate your unique tech talent at a leading pharmaceutical company.
Inauguration of new integrated Asian Veterinary R&D Center in China Inauguration of new integrated Asian Veterinary R&D Center in China Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Making-more-health-together-2021 Making-more-health-together-2021 1,200 participants from around the world join virtual convention on November 11-12
cat feline diabetes medication treatment eu approval cat feline diabetes medication treatment eu approval Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Partnering-with-google-in-quantum-computing Partnering-with-google-in-quantum-computing New cooperation with Google explores the potentials of quantum computing for pharma R&D.
First Translational Medicine Award awarded First Translational Medicine Award awarded The Award recognizes the research that has the highest translational potential
Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors
AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen
BTD for GlyT1 in Schizophrenia BTD for GlyT1 in Schizophrenia Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Stem cell therapy for tendon and ligament injuries in horses Stem cell therapy for tendon and ligament injuries in horses A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
PREVEXXION® RN: Marek’s disease vaccine available in EU UK PREVEXXION® RN: Marek’s disease vaccine available in EU UK Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
Approval for Aservo EquiHaler equine asthma therapy Approval for Aservo EquiHaler equine asthma therapy Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy